Invokana (canagliflozin) and Jardiance (empagliflozin) are both SGLT2 inhibitors: once-daily pills that lower blood sugar by making the kidneys pass extra glucose in the urine. They lower blood sugar by similar amounts. The bigger difference is who else they are approved for.
- Jardiance has the broader approvals: besides type 2 diabetes, it is approved for adults with heart failure (with or without diabetes) and adults with chronic kidney disease (with or without diabetes).
- Invokana is diabetes-only: it is approved to lower blood sugar and to cut heart and kidney risks in people with type 2 diabetes, including those with diabetic kidney disease.
- Children: both are now approved for type 2 diabetes in children aged 10 and older.
- Doses: Jardiance 10 mg or 25 mg once daily; Invokana 100 mg or 300 mg once daily, before the first meal.
- Shared side effects: genital yeast infections, urinary tract infections, dehydration, and rare ketoacidosis and Fournier’s gangrene.
- Amputation: the risk was first flagged with Invokana, which carried a boxed warning from 2017 until 2020. Since 2025, the labels treat it as a possible class-wide risk.
This is general information, not medical advice. Don’t switch between diabetes medicines on your own. Talk to your doctor or pharmacist about which drug suits your kidney function, heart history and other medicines.
Invokana vs Jardiance at a glance
| Invokana (canagliflozin) | Jardiance (empagliflozin) | |
|---|---|---|
| Made by | Janssen | Boehringer Ingelheim and Eli Lilly |
| First US approval | 2013 | 2014 |
| Doses | 100 mg or 300 mg once daily | 10 mg or 25 mg once daily |
| When to take | Before the first meal of the day | Morning, with or without food |
| Type 2 diabetes (adults and children 10+) | Yes | Yes |
| Heart protection in type 2 diabetes | Reduces heart attack, stroke and CV death in people with heart disease | Reduces CV death in people with heart disease |
| Heart failure without diabetes | No | Yes |
| Chronic kidney disease without diabetes | No | Yes |
| Diabetic kidney disease | Yes (with albuminuria) | Covered by its CKD approval |
| Combination pills | Invokamet, Invokamet XR (with metformin) | Synjardy (metformin), Glyxambi (linagliptin), Trijardy XR |
How SGLT2 inhibitors work
Your kidneys filter glucose out of the blood every day and then reabsorb almost all of it. Sodium-glucose co-transporter 2 (SGLT2) is the protein in the kidney tubules that does most of that reabsorption. Blocking it means roughly 60 to 100 grams of glucose a day, about 240 to 400 calories, leaves the body in the urine instead.
The results are lower blood sugar, a modest drop in weight (usually 2 to 3 kg) and a small fall in blood pressure. Because the effect does not depend on insulin, SGLT2 inhibitors rarely cause low blood sugar on their own.
Their heart and kidney benefits go beyond sugar control. Researchers think they reduce pressure inside the kidney’s filtering units, lower fluid overload and shift heart metabolism in helpful ways. That is why empagliflozin and dapagliflozin protect people with heart failure or kidney disease even when they do not have diabetes.
Canagliflozin is slightly less selective than empagliflozin: at the 300 mg dose it also partly blocks SGLT1 in the gut, which slightly blunts the rise in blood sugar after a meal. In practice the blood sugar lowering of the two drugs is similar.
Blood sugar lowering: which is stronger?
In their own trials, both lowered HbA1c by roughly 0.5 to 1.0 percentage points when added to metformin. Indirect comparisons and meta-analyses suggest canagliflozin 300 mg may lower HbA1c a little more than empagliflozin 25 mg, but the difference is small (about 0.1 to 0.2 points) and has not been tested head-to-head in a large trial.
For most people, the choice between them does not come down to blood sugar. It comes down to heart and kidney evidence, insurance coverage, kidney function and side effect concerns.
Heart and kidney evidence
Jardiance (empagliflozin)
- EMPA-REG OUTCOME (2015): in about 7,000 adults with type 2 diabetes and established heart disease, empagliflozin reduced cardiovascular death by 38% and hospitalization for heart failure by 35% compared with placebo. It was the first diabetes drug to show a reduction in cardiovascular death.
- EMPEROR-Reduced (2020) and EMPEROR-Preserved (2021): in people with heart failure, with or without diabetes, empagliflozin reduced the combined risk of cardiovascular death or heart failure hospitalization by about 25% and 21%. Together they cover the whole range of ejection fractions.
- EMPA-KIDNEY (2022): in 6,609 people with chronic kidney disease, with or without diabetes, empagliflozin reduced kidney disease progression or cardiovascular death by 28%.
Invokana (canagliflozin)
- CANVAS program (2017): in about 10,000 adults with type 2 diabetes and high cardiovascular risk, canagliflozin reduced the combined risk of heart attack, stroke or cardiovascular death by 14%. It also showed an unexpected increase in amputations (about 6 vs 3 per 1,000 patient-years), mostly of toes and the middle of the foot.
- CREDENCE (2019): in 4,401 people with type 2 diabetes and kidney disease with albuminuria, canagliflozin reduced the risk of kidney failure, doubling of creatinine, or kidney or cardiovascular death by 30%. The trial was stopped early because the benefit was so clear. It was the first big win for kidney protection in diabetes in almost two decades.
Both drugs therefore have strong outcome data in type 2 diabetes. Jardiance’s advantage is that its benefits have also been proven, and FDA-approved, in people without diabetes who have heart failure or kidney disease.
Dosing and kidney function
| Invokana | Jardiance | |
|---|---|---|
| Starting dose | 100 mg once daily before the first meal | 10 mg once daily in the morning |
| Maximum dose | 300 mg once daily | 25 mg once daily (for blood sugar) |
| Heart failure or CKD dose | Not applicable | 10 mg once daily |
| eGFR 30 to 59 | Limited to 100 mg | 10 mg suitable for heart and kidney uses; less blood sugar effect |
| eGFR below 30 | Do not start; people with albuminuria already on it may continue 100 mg for kidney protection | Can be started down to eGFR 20 for heart failure or CKD; not recommended for blood sugar alone |
| Dialysis | Not recommended | Not recommended |
As kidney function falls, both drugs lower blood sugar less, because less glucose is filtered. Their heart and kidney protection, however, persists at lower eGFR levels, which is why they are kept going for those reasons.
Interactions to know
- Insulin and sulfonylureas (glipizide, glimepiride, glyburide): the combination can cause low blood sugar; your doctor may lower their dose.
- Diuretics (water pills): both drugs add to fluid loss, raising the risk of dehydration and low blood pressure.
- Invokana and digoxin: canagliflozin raises digoxin levels slightly; digoxin levels should be monitored.
- Invokana and enzyme inducers: rifampin, phenytoin, phenobarbital and ritonavir lower canagliflozin levels. The label suggests raising the dose to 200 mg and then 300 mg if needed and kidney function allows.
- Lithium: both can lower lithium levels, so these need checking.
Side effects compared
Because they work the same way, the two drugs share most side effects.
| Side effect | What to know |
|---|---|
| Genital yeast infections | The most common side effect of both, especially in women and uncircumcised men. Good hygiene helps; most are easily treated. |
| Urinary tract infections | Slightly more common. Rarely, serious kidney infections (pyelonephritis) or urosepsis. |
| Increased urination and thirst | Expected in the first weeks. |
| Dehydration and low blood pressure | More likely in older adults, people on diuretics and those with reduced kidney function. |
| Ketoacidosis | Rare but serious; can occur with normal or only mildly raised blood sugar (“euglycemic DKA”). |
| Fournier’s gangrene | A very rare, serious infection of the genital area. |
| Lower limb amputation | Seen first with canagliflozin; labels now say SGLT2 inhibitors may increase risk. |
| Bone fractures | An increase was seen with canagliflozin in the CANVAS program; not seen consistently with empagliflozin. |
The amputation question
The CANVAS program found roughly double the rate of lower limb amputations with canagliflozin. In 2017, the FDA added a boxed warning to Invokana. As more data came in, including the CREDENCE trial, where the increase was not significant, the FDA concluded the risk was lower than first thought, and in August 2020 it removed the boxed warning while keeping a warning in the label.
Since then, the Jardiance label has added a lower limb amputation warning too (October 2025), and the medication guides now say SGLT2 inhibitors as a class may increase the risk. Whether canagliflozin carries more risk than others is still debated. Either way, people with peripheral artery disease, foot ulcers, neuropathy or a past amputation need careful foot care and discussion with their doctor before starting.
Ketoacidosis and surgery
Diabetic ketoacidosis (DKA) is a dangerous buildup of acids in the blood. With SGLT2 inhibitors it can happen even when blood sugar is not very high, so it can be missed. The risk rises with illness, vomiting, very low-carbohydrate diets, heavy alcohol use and surgery.
The FDA advises stopping canagliflozin and empagliflozin at least 3 days before planned surgery (dapagliflozin too; ertugliflozin 4 days) and restarting only once you are eating and drinking normally. Seek urgent care for nausea, vomiting, stomach pain, unusual tiredness or trouble breathing, even if your blood sugar seems normal.
Who might choose which?
| Situation | Likely preference |
|---|---|
| Heart failure, with or without diabetes | Jardiance (FDA-approved for heart failure) |
| Chronic kidney disease without diabetes | Jardiance (FDA-approved for CKD) |
| Type 2 diabetes with diabetic kidney disease and albuminuria | Either; both have strong data (CREDENCE for Invokana, EMPA-KIDNEY for Jardiance) |
| Type 2 diabetes and established heart disease | Either; both reduce cardiovascular events |
| Peripheral artery disease, foot ulcers or past amputation | Extra caution with any SGLT2 inhibitor; many doctors avoid canagliflozin |
| Osteoporosis or high fracture risk | Many doctors prefer empagliflozin |
| Cost or insurance | Whichever your plan covers best; Jardiance is more widely preferred on US formularies |
In everyday US practice, Jardiance is prescribed far more often than Invokana, largely because of its heart failure and CKD approvals and formulary position. Dapagliflozin (Farxiga), another SGLT2 inhibitor, has a similar heart failure and CKD profile to Jardiance.
Practical tips if you take either
- Drink enough fluid, especially in hot weather and during exercise.
- Keep the genital area clean and dry; report itching, discharge or pain early.
- Pause the drug on “sick days” when you can’t eat or drink normally, if your doctor agrees, and restart once you are well.
- Check your feet daily for sores, color changes or pain, especially if you have neuropathy or poor circulation.
- Expect sugar in your urine. Urine glucose tests will be positive and are no longer useful for monitoring.
- Tell every surgeon and anesthetist you take an SGLT2 inhibitor.
Frequently asked questions
Which is better, Invokana or Jardiance?
Neither is better for everyone. They lower blood sugar by similar amounts. Jardiance is also approved for heart failure and chronic kidney disease in people without diabetes, while Invokana has strong kidney data in diabetic kidney disease. The right choice depends on your heart and kidney health, side effect risks and insurance.
Can you switch from Invokana to Jardiance?
Yes, doctors switch between SGLT2 inhibitors, usually stopping one and starting the other the next day. Typical equivalent starting doses are Invokana 100 mg and Jardiance 10 mg. Only switch under your doctor’s direction.
Do Invokana and Jardiance cause weight loss?
Usually a modest amount, about 2 to 3 kg on average, because glucose (and its calories) is lost in the urine. They are not approved as weight-loss drugs.
Does Invokana still have a boxed warning for amputation?
No. The FDA removed the boxed warning in August 2020 after newer data suggested the risk was lower than first thought. An amputation warning remains in the label, and labels now say SGLT2 inhibitors as a class may increase the risk.
Can Jardiance be used without diabetes?
Yes. Jardiance is FDA-approved for adults with heart failure and adults with chronic kidney disease at risk of progression, whether or not they have diabetes. Invokana is only approved for people with type 2 diabetes.
Should I stop Jardiance or Invokana before surgery?
Usually yes. The FDA recommends stopping canagliflozin and empagliflozin at least 3 days before scheduled surgery to lower the risk of ketoacidosis. Your surgical team will tell you when to restart.
Are there generics for Invokana or Jardiance?
Not yet in the US as of late 2026. Both are brand-only, although manufacturer savings programs and insurance coverage vary.
References
- FDA. INVOKANA (canagliflozin) prescribing information, revised 6/2026
- FDA. JARDIANCE (empagliflozin) prescribing information, revised 10/2025
- FDA. FDA removes Boxed Warning about risk of leg and foot amputations for canagliflozin, 2020
- Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373:2117-2128
- Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes (CANVAS). N Engl J Med. 2017;377:644-657
- Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). N Engl J Med. 2019;380:2295-2306
- The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-127
About this article
Written by the Health Linear Editorial Team from primary sources such as FDA prescribing information, DailyMed, NIH and peer-reviewed studies, which are linked in the article. Last updated October 30, 2026.
Read our editorial process and medical disclaimer. Spotted an error? Tell us and we will correct it.